Issue Date: February 28, 2011
Bruker has signed an agreement to buy Michrom Bioresources, an Auburn, Calif.-based supplier of liquid chromatography instruments and consumables for proteomic researchers. Bruker says that Michrom’s business, which had revenues of $3 million in 2010, will complement its mass spectrometry product line.
Rhodia has taken an interest in a venture capital fund that expects to raise about $200 million for investments in energy, advanced materials, and environmental start-up firms. The fund, to be managed by Paris-based Aster Capital, includes other investors: power components maker Alstom and energy management specialist Schneider Electric.
Amyris will supply sugar-derived farnesene to Givaudan, which plans to develop it as a building block for a proprietary fragrance ingredient. Last year, Amyris agreed to collaborate with Firmenich on a biobased flavor and fragrance ingredient to be manufactured by Amyris (C&EN, Nov. 15, 2010, page 19).
LanzaTech, a New Zealand renewable chemicals and fuels start-up, has signed an agreement with South Korean conglomerate Posco. LanzaTech will use its gas fermentation technology to convert flue gases from Posco’s steel-making facility to ethanol and other products.
Vical, a San Diego-based biopharmaceuticals firm, has extended its pact with the U.S. Naval Medical Research Center for the development of vaccines against infectious diseases. Vical, which has already developed a DNA vaccine against the H1N1 flu virus that is undergoing Phase I testing, will now work on applying its technology to combat new pathogens in the early stages of outbreaks.
Monsanto has acquired Divergence, a privately held St. Louis-based biotechnology research firm. Monsanto says it plans to use Divergence’s expertise in parasitic nematodes to develop novel seed nematicide treatments.
Carbogen Amcis, a pharmaceuticals contract manufacturing firm, is shedding about 60 jobs as part of a restructuring of its operations in Switzerland, where it has roughly 350 workers. Three sites—Bubendorf, Aarau, and Hunzenschwil—will be affected by the changes, which Carbogen says are necessary as a result of delayed effects of the financial crisis and the strong Swiss franc. Carbogen is owned by India’s Dishman Group.
Viropro, an Irvine, Calif.-based contract manufacturing firm, has agreed to pay $21 million for Alpha Biologics, a Malaysia-based process development and biomanufacturing firm. Viropro gains a mammalian cell production facility in Penang Science Park, in Malaysia, that U.S. regulators will inspect in the coming months.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society